Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on October 22, 2018, regarding events occurring on October 17, 2018. The filing details the entry into a material definitive agreement and the creation of a direct financial obligation through a private placement of convertible senior notes.
Key Financial Metrics and Transaction Details
- Debt Issuance: $150.0 million aggregate principal amount of 1.50% convertible senior notes due 2025.
- Net Proceeds: Approximately $144.8 million after deducting fees and estimated expenses.
- Use of Proceeds: Net proceeds were loaned to Evolent Health LLC for working capital and general corporate purposes.
- Interest Rate: 1.50% per annum, payable semiannually in arrears beginning April 15, 2019.
- Maturity Date: October 15, 2025.
- Conversion Terms: Initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount (approx. $33.43 per share), representing a 32.50% premium over the October 17, 2018 closing price.
- Option: Purchasers hold an option to purchase up to an additional $22.5 million of notes.
Material Changes and Terms
The Company entered into a Purchase Agreement with J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC. The notes are convertible at the Company's election into cash, shares, or a combination thereof. Holders may require repurchase upon a fundamental change at 100% of principal plus accrued interest. The Company may not redeem the notes prior to October 20, 2022, unless specific stock price conditions are met thereafter.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, revenue outlook, or management commentary on operational performance. The primary risk disclosed relates to the dilution potential from the conversion of the notes and the obligation to service the new debt. The filing incorporates by reference the full text of the Purchase Agreement and Indenture for complete terms.
Key Facts for Investor Verification
- Verify the exact net proceeds received ($144.8 million) and the specific allocation of funds to Evolent Health LLC.
- Confirm the impact of the 32.50% conversion premium on potential future dilution (initially convertible into 4,487,025 shares).
- Review the "fundamental change" repurchase provisions and redemption restrictions prior to October 2022.
- Check if the $22.5 million option was subsequently exercised by the purchasers.
- Examine the full Indenture (Exhibit 4.1) for covenants and default conditions not detailed in the summary.